Investigating biomarkers in patients with post-COVID-19 symptoms
Post-COVID-19 Outpatient Care and Biomarkers for Persisting Symptoms of Post-COVID-19 Disease - A Prospective Registry and Biobank
This study is trying to see if certain blood markers in people with ongoing symptoms after COVID-19 can help us understand their condition better and predict how they might feel in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT05398952 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a large blood biobank and examine levels of circulating inflammatory biomarkers and non-coding RNAs in patients experiencing persistent symptoms after COVID-19. It will also assess the correlation between these biomarkers and the severity of symptoms, as well as their diagnostic and prognostic value. Patients will be recruited from the Post-COVID-19 outpatient clinic at the Medical University of Vienna, with additional comparison groups of vaccinated patients with heart failure and healthy vaccinated volunteers. The study will involve clinical examinations and laboratory tests to gather comprehensive data.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 90 who have recovered from a confirmed SARS-CoV-2 infection and are experiencing persistent symptoms.
Not a fit: Patients currently participating in other SARS-CoV-2 medical treatment trials or those with clinically confirmed heart failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and targeted therapies for patients suffering from long-term effects of COVID-19.
How similar studies have performed: While there are ongoing studies on post-COVID-19 treatments, this investigation into biomarkers is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: For post-COVID patient group: * Age≥18to90years * Proven infection by SARS-CoV2, at least 3 weeks after recovery from the infection * Signed informed consent For HFrEF patient group: For vaccinated healthy volunteer control group: * Full vaccination against SARS-CoV2 at least 3 weeks before inclusion in the study * Signed informed consent Exclusion Criteria: * non-willingness to participate or withdrawal of informed consent * Clinically confirmed HFrEF (EF \<40%) * participation in any SARS-CoV-2 medical treatment trial * pregnancy
Where this trial is running
Vienna
- Department of Cardiology, Medical University of Vienna — Vienna, Austria (Recruiting)
Study contacts
- Principal investigator: Mariann Gyöngyösi, MD PhD — Medical University of Vienna
- Study coordinator: Mariann Gyöngyösi, MD PhD
- Email: mariann.gyongyosi@meduniwien.ac.at
- Phone: +4314040046140
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.